ANRIL and the 9p21 Beta-Cell Clock
The region of chromosome 9 known as 9p21 harbors one of the most
consistently replicated type 2 diabetes risk signals in the human genome.
rs564398 sits within CDKN2B-AS1 (ANRIL) | ANRIL stands for "antisense
non-coding RNA in the INK4 locus" — a long non-coding RNA transcribed
in the opposite direction from the CDKN2A and CDKN2B protein-coding genes
at 9p21. lncRNAs regulate nearby gene expression through chromatin
remodeling and other epigenetic mechanisms. — a long non-coding RNA
that modulates expression of the adjacent tumor suppressor genes CDKN2A
(p16) and CDKN2B (p15). These inhibitors act as brakes on cell division,
and in pancreatic beta cells they control how readily the insulin-producing
mass can renew itself.
rs564398 is a secondary signal at this locus, independent of but weaker
than the primary variant rs10811661 (~200 kb away). The T risk allele
carries a per-allele T2D odds ratio of approximately 1.08, compared
to ~1.24 for the primary signal. Both act through the same broad
mechanism — reducing glucose-stimulated beta-cell proliferative capacity
— but may tag distinct regulatory elements within the locus.
The Mechanism
The 9p21 locus regulates how effectively pancreatic beta cells can
replicate in response to metabolic demand. Unlike T2D variants that impair
acute insulin secretion per cell (e.g., TCF7L2 or SLC30A8), rs564398 acts
at the level of beta-cell mass maintenance | Beta cells must periodically
replace themselves as they age or are damaged by metabolic stress. The
total number of functional beta cells declines over decades if renewal
capacity is impaired, eventually reducing the pancreas's ability to secrete
enough insulin..
A functional study by Kong et al. 2018 | Kong Y et al. CDKN2A/B T2D
Genome-Wide Association Study Risk SNPs Impact Locus Gene Expression and
Proliferation in Human Islets. Diabetes 2018.
PMID:29432124 measured
BrdU incorporation (a direct index of cell division) in 43 human islet
preparations cultured at high versus normal glucose concentrations. Islets
carrying one or two T risk alleles at rs564398 showed significantly lower
glucose-stimulated proliferation than CC homozygous islets — directly
linking the variant to impaired beta-cell renewal under metabolic challenge.
Notably, rs564398 did not alter expression of p14, p15, p16, or MTAP in
islets, suggesting its mechanism operates through ANRIL at a regulatory
level distinct from simple CDKN2A/B transcript abundance.
The Evidence
The T risk allele at rs564398 was first reported as a T2D susceptibility
signal in the landmark WTCCC GWAS | Zeggini et al. Replication of
genome-wide association signals in UK samples reveals risk loci for type 2
diabetes. Science 2007. PMID:17463249,
where it reached genome-wide significance with OR 1.13 (95% CI 1.08–1.19,
p = 1×10⁻⁶). This was one of the largest initial T2D GWAS, covering ~1,900
cases from the WTCCC plus replication in ~3,700 additional cases.
The Cugino et al. 2012 meta-analysis | Cugino et al. Type 2 diabetes and
polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc
Dis 2012. PMID:21315566 of 22
chromosome 9p21 studies quantified the rs564398 signal at OR 1.08 (95% CI
1.05–1.12) with a population attributable risk of 6% — roughly half the
PAR of the primary rs10811661 signal (15%). A further meta-analysis |
Peng et al. The relationship between five widely-evaluated variants in
CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
Gene 2013. PMID:24012816 of
16 studies (20,029 cases, 24,419 controls) found a significant association
in Caucasians (OR 1.19, p=0.012) but not in Asians (OR 1.01, p=0.868),
with marked ethnic heterogeneity at this SNP.
The C allele frequency varies substantially across populations — ~41% in
Europeans, ~34% globally, ~13% in East Asians, and ~7% in Africans. This
population stratification mirrors the primary 9p21 signal and may partially
explain the stronger T2D associations observed in European cohorts.
Practical Actions
Because the 9p21 locus reduces beta-cell renewal capacity rather than
impairing acute insulin secretion, the relevant intervention strategy
centers on reducing cumulative metabolic demand on a beta-cell pool that
has limited ability to self-replenish. This means:
- Keeping postprandial glucose excursions small by choosing low-glycemic-load carbohydrates (legumes, lentils, non-starchy vegetables) reduces the secretory burden on each individual beta cell.
- Periodic fasting glucose and HbA1c monitoring allows detection of gradually declining beta-cell reserve before frank diabetes develops.
- Minimizing direct beta-cell stressors (excess fructose, saturated fat overload) is specifically relevant when renewal capacity is genetically constrained.
Interactions
rs564398 and the primary 9p21 SNP rs10811661 are approximately 104 kb apart
and are not in complete linkage disequilibrium — they may represent
independent regulatory signals within the locus. Carrying risk alleles at
both SNPs could compound the impairment of beta-cell renewal through
distinct regulatory elements within ANRIL and flanking chromatin.
Beyond the 9p21 locus, the 9p21 beta-cell mass signal acts through a
mechanism completely distinct from the TCF7L2 pathway (rs7903146), which
impairs incretin-stimulated insulin secretion per cell. Individuals
carrying risk alleles at both loci face additive T2D susceptibility from
two independent mechanisms: reduced beta-cell mass (9p21) and reduced
per-cell insulin output (TCF7L2).
The ANRIL locus also carries well-established cardiovascular disease
associations; rs564398 has been linked to coronary artery disease risk in
a Turkish cohort, particularly in females, highlighting the pleiotropic
role of this genomic region.
All Genotypes
Protective genotype — lowest T2D risk at this secondary 9p21 signal
You carry two copies of the protective C allele at rs564398. About 12% of people globally share this genotype, which confers the lowest type 2 diabetes risk at this secondary 9p21 signal. Functional studies show that CC homozygous islets have the highest glucose-stimulated beta-cell proliferation of the three genotypes, suggesting your insulin-producing cells retain greater renewal capacity at this locus. The C allele is substantially more common in Europeans (~41%) than in East Asians (~13%) or Africans (~7%), so CC is notably more prevalent in European-ancestry populations.
One T risk allele — modestly elevated T2D susceptibility
You carry one copy of the T risk allele at rs564398 and one protective C allele. About 45% of people globally share this CT genotype. Under the additive model, one T allele confers approximately 8% increased relative risk for type 2 diabetes (OR ~1.08 per allele from the Cugino et al. 2012 meta-analysis). This is a modest effect — the 9p21 secondary signal at rs564398 is roughly one-third as strong as the primary signal at rs10811661. The mechanism appears to be a mild impairment of glucose-stimulated beta-cell proliferation in pancreatic islets, reducing the capacity for insulin-producing cells to renew themselves in response to metabolic demand.
Two T risk alleles — highest T2D susceptibility at this secondary 9p21 signal
You carry two copies of the T risk allele at rs564398. About 43% of people globally share this TT genotype. Under the additive model, two T alleles confer approximately 17% increased relative risk for type 2 diabetes (OR ~1.08² ≈ 1.17). Functional studies confirm that TT homozygous pancreatic islets show the lowest glucose-stimulated beta-cell proliferation, meaning your insulin-producing cells have the greatest impairment of renewal capacity at this locus. This is a secondary signal at the 9p21 locus — weaker than the primary rs10811661 variant — but it independently contributes to T2D susceptibility through the same broad mechanism of reduced beta-cell mass maintenance. About 43% of the global population carries this genotype.